Project description:GA-MSCs extracted from glioblastoma specimens classified as WHO grade IV (confirmed by pathological examination) were cultured in T25 culture flasks. Once the cell density reached approximately 70%-80%, the cells were treated with either DMEM (control condition) or GSC-CM (experimental condition). Each condition was tested in triplicate. After three days of incubation, total RNA was extracted using the TRIzol reagent (TAKARA, Japan). RNA quality was assessed using a Nanodrop 2000 and an Agilent Bioanalyzer 2100, and only samples meeting quality control criteria were included in the microarray analysis. The RNA samples were poly-A-tailed, biotin-labeled, and analyzed using the Affymetrix GN-GeneChip Human Clariom D Array 2.0 (Affymetrix, USA).
Project description:We used microarray global gene expression profiling to investigate the effect caused by neuro-condition media of MSCs on the growth and pluripotency of glioma stem cells. The effect was specifically investigated for cell cycle arrest, cell differentiation, invasion and self renewal ability of glioma stem cells,
Project description:This project is described about the detailed characterization of 3D spheroid mesenchymal stem cells (MSCs). Specifically, authors showed the dynamic action towards EMT in 3D MSCs and the potential of EMT-enhanced “naïve” mesenchymal phenotype.
Project description:To characterize and compare XF-iMSC (XenoFree-induced Mesenchymal stem/stromal cells) and various types of MSCs (Adipose-, Bone marrow-, Unbilical cord-derived), we performed a transcriptome analysis of these MSCs
Project description:Mesenchymal stromal cells (MSCs) are used for ameliorating liver fibrosis and aiding liver regeneration after cirrhosis; Here, we analyzed the therapeutic potential of small extracellular vesicles (sEVs) derived from interferon-γ (IFN-γ) pre-conditioned MSCs (γ-sEVs). to anlyze the proteins in sEVs, proteomics of small extracellular vesicles (sEVs) from adipose tissue derived mesenchymal stem cells (AD-MSCs) stimulated with or without IFN-γ were performed.
Project description:Primary human bone marrow-derived mesenchymal stem cells (MSCs) were treated with recombinant human TGFb1 (10ng/ml) for different time points (1, 3, 7, 14, 24 hours)
Project description:Primary human bone marrow-derived mesenchymal stem cells (MSCs) were treated with recombinant human TNFa (50ng/ml) for different time points (1, 3, 7, 14, 24 hours)
Project description:ZNF145 is shown to be upregulated during three linage differentiation of MSCs especially in chondrogenesis. To understand the molecular basis of ZNF145 underlying MSCs, targets of ZNF145 in MSCs are determined by microarray We used microarrays to detail the change in gene expression profile upon overexpression of ZNF145 compared with control in undifferentiated MSCs Control MSCs and ZNF145-overexpressing MSCs are processed for RNA extraction and hybridization on Affymetrix microarrays. To that end, we overexpressed ZNF145 in two patient-derived human MSCs.
Project description:The instrinsic regenerative capacity of human fetal cardiac mesenchymal stromal cells (MSCs) has not been fully characterised. Here we demonstrate that we can expand cells with characteristics of cardiovascular progenitor cells from the MSC population of human fetal hearts with only minor fluctuations over time in culture (from day 15 to day 48). We used microarray to compare the gene-expression profile of cultured human fetal cardiac MSCs over time (from day 15 to day 48). MSCs from human fetal hearts were cultured on GelTrex in a defined medium stimulating the canonical Wnt/beta-catenin pathway. Samples from three different time points (day 15, 27 and 48) were compared on microarray.